1.56 USD
+0.04 (+2.63%)
CLGN gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 530 industry peers in the Biotechnology industry. CLGN scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. CLGN is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year CLGN has reported negative net income.
In the past year CLGN has reported a negative cash flow from operations.
CLGN had negative earnings in 4 of the past 5 years.
CLGN had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of -86.31%, CLGN is doing worse than 71.51% of the companies in the same industry.
With a Return On Equity value of -130.68%, CLGN is not doing good in the industry: 62.08% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -86.31% | ||
| ROE | -130.68% | ||
| ROIC | N/A |
ROA(3y)-51.39%
ROA(5y)-41.38%
ROE(3y)-66.85%
ROE(5y)-65.77%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 63.03%, CLGN is in the better half of the industry, outperforming 79.06% of the companies in the same industry.
The Profit Margin and Operating Margin are not available for CLGN so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 63.03% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
CLGN does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CLGN has about the same amount of shares outstanding.
The number of shares outstanding for CLGN has been increased compared to 5 years ago.
There is no outstanding debt for CLGN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
Based on the Altman-Z score of -11.76, we must say that CLGN is in the distress zone and has some risk of bankruptcy.
CLGN has a worse Altman-Z score (-11.76) than 75.85% of its industry peers.
There is no outstanding debt for CLGN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -11.76 |
ROIC/WACCN/A
WACC8.6%
2.3 Liquidity
CLGN has a Current Ratio of 3.66. This indicates that CLGN is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 3.66, CLGN perfoms like the industry average, outperforming 44.34% of the companies in the same industry.
A Quick Ratio of 3.45 indicates that CLGN has no problem at all paying its short term obligations.
The Quick ratio of CLGN (3.45) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.66 | ||
| Quick Ratio | 3.45 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 25.00% over the past year.
Looking at the last year, CLGN shows a very strong growth in Revenue. The Revenue has grown by 280.77%.
Measured over the past years, CLGN shows a very negative growth in Revenue. The Revenue has been decreasing by -25.99% on average per year.
EPS 1Y (TTM)25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%28.95%
Revenue 1Y (TTM)280.77%
Revenue growth 3Y-67.95%
Revenue growth 5Y-25.99%
Sales Q2Q%1825%
3.2 Future
The Earnings Per Share is expected to grow by 25.70% on average over the next years. This is a very strong growth
CLGN is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 103.99% yearly.
EPS Next Y77.99%
EPS Next 2Y40.31%
EPS Next 3Y25.7%
EPS Next 5YN/A
Revenue Next Year422.12%
Revenue Next 2Y211.49%
Revenue Next 3Y103.99%
Revenue Next 5YN/A
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
CLGN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year CLGN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as CLGN's earnings are expected to grow with 25.70% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.31%
EPS Next 3Y25.7%
5. Dividend
5.1 Amount
CLGN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NASDAQ:CLGN (12/22/2025, 4:30:01 PM)
1.56
+0.04 (+2.63%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners14.21%
Inst Owner Change-18.55%
Ins Owners29.81%
Ins Owner ChangeN/A
Market Cap19.94M
Revenue(TTM)2.48M
Net Income(TTM)-12.16M
Analysts82.5
Price Target11.73 (651.92%)
Short Float %1.01%
Short Ratio3.21
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-183.43%
Min EPS beat(2)-270.78%
Max EPS beat(2)-96.08%
EPS beat(4)0
Avg EPS beat(4)-151.67%
Min EPS beat(4)-270.78%
Max EPS beat(4)-21.21%
EPS beat(8)0
Avg EPS beat(8)-113.94%
EPS beat(12)1
Avg EPS beat(12)164.56%
EPS beat(16)1
Avg EPS beat(16)88.54%
Revenue beat(2)0
Avg Revenue beat(2)-95.77%
Min Revenue beat(2)-98.44%
Max Revenue beat(2)-93.1%
Revenue beat(4)0
Avg Revenue beat(4)-69.54%
Min Revenue beat(4)-98.44%
Max Revenue beat(4)-23.83%
Revenue beat(8)0
Avg Revenue beat(8)-74.59%
Revenue beat(12)3
Avg Revenue beat(12)-42.33%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-1.61%
Revenue NQ rev (1m)-4.25%
Revenue NQ rev (3m)-4.25%
Revenue NY rev (1m)-1.23%
Revenue NY rev (3m)-1.23%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 8.06 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 2.14 | ||
| P/tB | 2.16 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.02
EYN/A
EPS(NY)-0.05
Fwd EYN/A
FCF(TTM)-0.78
FCFYN/A
OCF(TTM)-0.78
OCFYN/A
SpS0.19
BVpS0.73
TBVpS0.72
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -86.31% | ||
| ROE | -130.68% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 63.03% | ||
| FCFM | N/A |
ROA(3y)-51.39%
ROA(5y)-41.38%
ROE(3y)-66.85%
ROE(5y)-65.77%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.18
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 7.68% | ||
| Cap/Sales | 2.91% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.66 | ||
| Quick Ratio | 3.45 | ||
| Altman-Z | -11.76 |
F-Score4
WACC8.6%
ROIC/WACCN/A
Cap/Depr(3y)85.11%
Cap/Depr(5y)108.12%
Cap/Sales(3y)180.83%
Cap/Sales(5y)112.23%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%28.95%
EPS Next Y77.99%
EPS Next 2Y40.31%
EPS Next 3Y25.7%
EPS Next 5YN/A
Revenue 1Y (TTM)280.77%
Revenue growth 3Y-67.95%
Revenue growth 5Y-25.99%
Sales Q2Q%1825%
Revenue Next Year422.12%
Revenue Next 2Y211.49%
Revenue Next 3Y103.99%
Revenue Next 5YN/A
EBIT growth 1Y32.91%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-108.62%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-164.01%
OCF growth 3YN/A
OCF growth 5YN/A
COLLPLANT BIOTECHNOLOGIES LT / CLGN FAQ
What is the fundamental rating for CLGN stock?
ChartMill assigns a fundamental rating of 3 / 10 to CLGN.
Can you provide the valuation status for COLLPLANT BIOTECHNOLOGIES LT?
ChartMill assigns a valuation rating of 1 / 10 to COLLPLANT BIOTECHNOLOGIES LT (CLGN). This can be considered as Overvalued.
Can you provide the profitability details for COLLPLANT BIOTECHNOLOGIES LT?
COLLPLANT BIOTECHNOLOGIES LT (CLGN) has a profitability rating of 1 / 10.
What is the financial health of COLLPLANT BIOTECHNOLOGIES LT (CLGN) stock?
The financial health rating of COLLPLANT BIOTECHNOLOGIES LT (CLGN) is 6 / 10.